NuChem Sciences Acquires IniXium

Sygnature Discovery Acquires NuChem Sciences

August 1, 2023

Biotechnology

UK-based integrated drug discovery CRO Sygnature Discovery has acquired Montreal-headquartered NuChem Sciences, one of North America's largest discovery contract research organisations. The deal expands Sygnature's global footprint and capabilities in medicinal chemistry, DMPK, structural biology and in vitro/in vivo pharmacology, strengthening its position in the North American market.

X-Chem Acquires IntelliSyn and AviSyn to Expand Drug Discovery Services

January 26, 2021

Biotechnology

X-Chem, a portfolio company of GHO Capital, has acquired Montreal-based IntelliSyn and its US-based sister company AviSyn to extend its drug discovery offering into medicinal chemistry, custom synthesis and scale-up process chemistry. The deal integrates downstream hit validation and lead optimisation capabilities into X-Chem’s DNA-Encoded Library (DEL) platform, enabling a streamlined screen-to-lead service for pharma and biotech clients; financial terms were not disclosed.

Sanofi Acquires Amunix Pharmaceuticals

December 21, 2021

Biotechnology

Sanofi has entered into an agreement to acquire Amunix Pharmaceuticals for an upfront payment of approximately $1.0 billion plus up to $225 million in potential development milestones. The acquisition gives Sanofi Amunix’s Pro‑XTEN/XPAT/XPAC masking technology and a pipeline of conditionally activated T‑cell engagers and cytokine therapies (including lead candidate AMX‑818), expanding Sanofi’s immuno‑oncology capabilities.

Schrödinger Acquires XTAL BioStructures

January 14, 2022

Biotechnology

Schrödinger, Inc. acquired XTAL BioStructures, Inc., a Natick, Massachusetts–based structural biology services provider, in an all-cash transaction that closed January 14, 2022 for $6 million. The acquisition brings protein production, purification, biophysical methods and X-ray crystallography capabilities in‑house to support Schrödinger's structure-based drug discovery platform and expand its experimental offerings for customers.

X-Chem Acquires Glamorous AI and ComInnex

October 29, 2021

Biotechnology

X-Chem, a GHO Capital-backed leader in DNA-encoded library (DEL) technology, has acquired AI drug-discovery specialist Glamorous AI and Budapest-based synthetic chemistry services provider ComInnex. The deals expand X-Chem’s machine-learning capabilities and synthetic chemistry capacity, broadening its global footprint and accelerating small-molecule discovery services for biopharma clients.

Novo Holdings Acquires Altasciences from Audax Private Equity

February 22, 2021

Healthcare Services

Novo Holdings has agreed to acquire Altasciences, a Laval, Canada–headquartered contract research and CDMO services provider, from Audax Private Equity. Altasciences— which operates six facilities across the U.S. and Canada and employs over 1,300 people—will remain led by CEO Chris Perkin and is expected to continue expanding domestically and internationally under Novo Holdings' ownership.